Variations in the Serum Concentrations of Soluble Fas and Soluble Fas Ligand in Vietnamese Patients Infected with Hepatitis B Virus

Journal of Medical Virology

Volumn 73, Issue 2, 2004, Pages 244-249

  Song, Le H ^a,b,c   Binh, Vu Q ^b   Duy, Dinh N ^b   Bock, Thomas C ^c   Kremsner, Peter G ^a,d   Luty, Adrian J F ^a,d   Mavoungou, Elie ^a,d  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Tran Hung Dao Hospital   (Viet Nam)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d ALBERT SCHWEITZER HOSPITAL   (Gabon)

Author keywords

Hepatitis B virus; Hepatocellular carcinoma (HCC); SFas sFasL

Indexed keywords

ALPHA FETOPROTEIN; FAS ANTIGEN; FAS LIGAND;

ADULT; ARTICLE; CHRONIC HEPATITIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; LIGAND BINDING; LIVER CELL; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; VIET NAM; VIRUS INFECTION;

ADULT; ALPHA-FETOPROTEINS; ANTIGENS, CD95; CARCINOMA, HEPATOCELLULAR; CARRIER STATE; DISEASE PROGRESSION; FAS LIGAND PROTEIN; FEMALE; HEPATITIS B; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; VIETNAM;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 2142758645     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20082     Document Type: Article

References (36)

1. Cascino I, Fiucci G, Papoff G, Ruberti G. 1995. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 154:2706-2713.
2. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD. 1994. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759-1762.
3. Chisari FV. 2000. Rous-Whipple Award Lecture. Viruses, immunity, and cancer: Lessons from hepatitis B. Am J Pathol 156:1117-1132. Review.
4. Chisari FV, Ferrari C. 1995. Hepatitis B virus immunopathology. Springer Semin Immunopathol 17:261-281. Review.
5. Depraetere V, Golstein P. 1997. Fas and other cell death signaling pathways. Semin Immunol 6:93-107.
6. Diao J, Garces R, Richardson CD. 2001. X protein of hepatitis B virus modulates cytokine and growth factor related signal transduction pathways during the course of viral infections and hepatocarcinogenesis. Cytokine Growth Factor Rev 12:189-205. Review.
7. Ehrmann J, Jr., Galuszkova D, Ehrmann J, Krc I, Jezdinska V, Vojtesek B, Murray PG, Kolao Z. 2000. Apoptosis-related proteins, BCL-2, BAX, FAS, FAS-L, and PCNA in liver biopsies of patients with chronic hepatitis B virus infection. Pathol Oncol Res 6:130-135.
8. Elmore LW, Hancock AR, Chang SF, Wang XW, Chang S, Callahan CP, Geller DA, Will H, Harris CC. 1997. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci USA 94:14707-14712.
9. Han HJ, Jung EY, Lee WJ, Jang KL. 2002. Cooperative repression of cyclin-dependent kinase inhibitor p21 gene expression by hepatitis B virus X protein and hepatitis C virus core protein. FEBS Lett 518:169-172.
10. Iio S, Hayashi N, Mita E, Ueda K, Mochizuki K, Hiramatsu N, Kanto T, Sasaki Y, Kasahara A, Hori M. 1998. Serum levels of soluble Fas antigen in chronic hepatitis C patients. J Hepatol 29:517-523.
11. Jodo S, Kobayashi S, Nakajima Y, Matsunaga T, Nakayama N, Ogura N, Kayagaki N, Okumura K, Koike T. 1998. Elevated serum levels of soluble Fas/ APO-1 (CD95) in patients with hepatocellular carcinoma. Clin Exp Immunol 112:166-171.
12. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, Yagita H. 1995. Metalloproteinase-mediated release of human Fas ligand 182:1777-1783.
13. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S. 1997. Essential roles of the Fas ligand in the development of hepatitis. Nat Med 3:409-413.
14. Koulentaki M, Valatas V, Xidakis K, Kouroumalis A, Petinaki E, Castanas E, Kouroumalis E. 2002. Matrix metalloproteinases and their inhibitors in acute viral hepatitis. J Viral Hepat 9:189-193.
15. Luo KX, Zhu YF, Zhang LX, He HT, Wang XS, Zhang L. 1997. In situ investigation of Fas/FasL expression in chronic hepatitis B infection and related liver diseases. J Viral Hepat 4:303-307.
16. Luo JC, Hwang SJ, Lai CR, Lu CL, Li CP, Tsay SH, Wu JC, Chang FY, Lee SD. 1998. Relationships between serum aminotransferase levels, liver histologies, and virological status in patients with chronic hepatitis C in Taiwan. J Gastroenterol Hepatol 13:685-690.
17. Mochizuki K, Hayashi N, Hiramatsu N, Katayama K, Kawanishi Y, Kasahara A, Fusamoto H, Kamada T. 1996. Fas antigen expression in liver tissues of patients with chronic hepatitis B. J Hepatol 24:1-7.
18. Nagata S. 1997. Apoptosis by death factor. Cell 6:355-365.
19. Nozawa K, Kayagaki N, Tokano Y, Yagita H, Okumura K, Hasimoto H. 1997. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum 40:1126-1129.
20. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F. 1999. Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: The Fas counterattack. Dis Esophagus 12:83-89. Review.
21. Ogden SK, Lee KC, Barton MC. 2000. Hepatitis B viral transactivator HBx alleviates p53-mediated repression of α-fetoprotein gene expression. J Biol Chem 275:27806-27814.
22. Pan J, Duan LX, Sun BS, Feitelson MA. 2001. Hepatitis B virus X protein protects against anti-Fas-mediated apoptosis in human liver cells by inducing NF-kappa B. J Gen Virol 82:171-182.
23. Rivero M, Crespo J, Fabrega E, Casafont F, Mayorga M, Gomez-Fleitas M, Pons-Romero F. 2002. Apoptosis mediated by the Fas system in the fulminant hepatitis by hepatitis B virus. J Viral Hepat 9: 107-113.
24. Shiota G, Oyama K, Noguchi N, Takano Y, Kitaoka S, Kawasaki H. 1998. Clinical significance of serum soluble Fas ligand in patients with acute self-limited and fulminant hepatitis. Res Commun Mol Pathol Pharmacol 101:3-12.
25. Song LH, Binh VQ, Duy DN, Bock CT, Kun JFJ, Kremsner PG, Luty AJF. 2003. Serum cytokine profiles associated with clinical presentation in Vietnamese infected with hepatitis B virus. J Clin Virol 28:93-103.
26. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR. 1996. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion? Nat Med 2:1361-1366.
27. Su F, Theodosis CN, Schneider RJ. 2001. Role of NF-kappaB and myc proteins in apoptosis induced by hepatitis B virus HBx protein. J Virol 75:215-225.
28. Suda T, Okazaki T, Naito Y, et al. 1995. Expression of the Fas ligand in cells of T cell lineage. J Immunol 6:3806-3813.
29. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. 1997. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 186:2045-2050.
30. Tanaka M, Itai T, Adachi M, Nagata S. 1998. Downregulation of Fas ligand by shedding. Nat Med 4:31-36.
31. Toyoda M, Kakizaki S, Horiguchi N, Sato K, Takayama H, Takagi H, Nagamine T, Mori M. 2000. Role of serum soluble Fas/soluble Fas ligand and TNF-alpha on response to interferon-alpha therapy in chronic hepatitis C. Liver 20:305-311.
32. Toyozaki T, Hiroe M, Tanaka M, Nagata S, Ohwada H, Marumo F. 1998. Levels of soluble Fas ligand in myocarditis. Am J Cardiol 82: 246-248.
33. Wang PS, Chen YM, Hsieh YL, Yu CF, Tsai CM, Perng RP. 2002. Pleural effusion and serum soluble fas-ligand levels are elevated in different clinical conditions. Lung 180:25-32.
34. Watanabe-Fukunaga R, Brannan CI, Itoh N, et al. 1992. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 6:1274-1279.
35. Webb SD, Sherratt JA, Fish RG. 2002. Cells behaving badly: A theoretical model for the Fas/FasL system in tumour immunology. Math Biosci 179:113-129.
36. Yoon J, Gores G. 2002. Death receptor-mediated apoptosis and the liver. J Hepatol 37:400.